Shangzhi David Xu

Dr. David Xu, MD, PhD, brings 30 years of drug development expertise focused on ADC development and clinical development. He leads end‑to‑end ADC programs via AI/ML, PK/PD modeling, and quantitative pharmacology to optimize design, linker chemistry, and translation with hands‑on IND/NDA submissions under FDA/ICH guidelines. Currently he is resided as President of Pharmconsulting LLC, and CTO of SpeedPharm (RDC) in Rochester, Minnesota, USA